open access

Vol 14, No 4 (2017)
Guidelines / Expert consensus
Published online: 2017-11-30
Get Citation

Polyunsaturated fatty acids combined with alpha-lipoic acid (Liponerv®) in mild cognitive impairment

Bernard Dżumaga
Psychiatria 2017;14(4):255-261.

open access

Vol 14, No 4 (2017)
Experts opinion
Published online: 2017-11-30

Abstract

brak

Abstract

brak
Get Citation

Keywords

brak

About this article
Title

Polyunsaturated fatty acids combined with alpha-lipoic acid (Liponerv®) in mild cognitive impairment

Journal

Psychiatria (Psychiatry)

Issue

Vol 14, No 4 (2017)

Article type

Guidelines / Expert consensus

Pages

255-261

Published online

2017-11-30

Bibliographic record

Psychiatria 2017;14(4):255-261.

Keywords

brak

Authors

Bernard Dżumaga

References (42)
  1. Reisberg B, Ferris S, Leon Mde, et al. Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Development Research. 1988; 15(2-3): 101–114.
  2. Carrasquillo MM, Crook JE, Pedraza O, et al. Aging, memory, and mild cognitive impairment. Int Psychogeriatr. 1997; 9 Suppl 1(7): 65–69.
  3. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2003; 2(1): 15–21.
  4. Unverzagt FW, Gao S, Baiyewu O, et al. Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology. 2001; 57(9): 1655–1662.
  5. Okhravi HR, Palmer RM. Mild cognitive impairment: challenges in research and in practice. Cleve Clin J Med. 2012; 79(12): 853–854.
  6. Barberger-Gateau P, Letenneur L, Deschamps V, et al. Fish, meat, and risk of dementia: cohort study. BMJ. 2002; 325(7370): 932–933.
  7. Barberger-Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology. 2007; 69(20): 1921–1930.
  8. van Gelder BM, Tijhuis M, Kalmijn S, et al. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr. 2007; 85(4): 1142–1147.
  9. Morris MC, Evans DA, Tangney CC, et al. Fish consumption and cognitive decline with age in a large community study. Arch Neurol. 2005; 62(12): 1849–1853.
  10. Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol. 2006; 63(11): 1545–1550.
  11. Boston PF, Bennett A, Horrobin DF, et al. Ethyl-EPA in Alzheimer's disease--a pilot study. Prostaglandins Leukot Essent Fatty Acids. 2004; 71(5): 341–346.
  12. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006; 63(10): 1402–1408.
  13. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010; 304(17): 1903–1911.
  14. Yurko-Mauro K, McCarthy D, Rom D, et al. MIDAS Investigators. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010; 6(6): 456–464.
  15. Vakhapova V, Cohen T, Richter Y, et al. Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial. Dement Geriatr Cogn Disord. 2010; 29(5): 467–474.
  16. Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1538–1544.
  17. Lee LK, Shahar S, Chin AV, et al. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2013; 225(3): 605–612.
  18. Sinn N, Milte CM, Street SJ, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr. 2012; 107(11): 1682–1693.
  19. Kotani S, Sakaguchi E, Warashina S, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res. 2006; 56(2): 159–164.
  20. Mazereeuw G, Lanctôt KL, Chau SA, et al. Effects of ω-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging. 2012; 33(7): 1482.e17–1482.e29.
  21. Cole GM, Frautschy SA. DHA may prevent age-related dementia. J Nutr. 2010; 140(4): 869–874.
  22. Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids. 2009; 81(2-3): 213–221.
  23. Maczurek A, Hager K, Kenklies M, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv Drug Deliv Rev. 2008; 60(13-14): 1463–1470.
  24. Hager K, Kenklies M, McAfoose J, et al. Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. J Neural Transm Suppl. 2007(72): 189–193.
  25. Fava A, Pirritano D, Plastino M, et al. The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease. J Neurodegener Dis. 2013; 2013: 454253.
  26. Shinto L, Quinn J, Montine T, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. J Alzheimers Dis. 2014; 38(1): 111–120.
  27. Hjorth E, Zhu M, Toro VC, et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimers Dis. 2013; 35(4): 697–713.
  28. Puskás LG, Kitajka K, Nyakas C, et al. Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc Natl Acad Sci U S A. 2003; 100(4): 1580–1585.
  29. Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem. 2007; 101(3): 577–599.
  30. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol . 2010; 177: 1576–1591.
  31. Tanaka K, Farooqui AA, Siddiqi NJ, et al. Effects of docosahexaenoic Acid on neurotransmission. Biomol Ther (Seoul). 2012; 20(2): 152–157.
  32. Rao JS, Ertley RN, Lee HJ, et al. n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry. 2007; 12(1): 36–46.
  33. Akbar M, Calderon F, Wen Z, et al. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A. 2005; 102(31): 10858–10863.
  34. Lukiw WJ, Cui JG, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005; 115(10): 2774–2783.
  35. Mukherjee PK, Marcheselli VL, Serhan CN, et al. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A. 2004; 101(22): 8491–8496.
  36. Gamoh S, Hashimoto M, Sugioka K, et al. Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience. 1999; 93(1): 237–241.
  37. Gamoh S, Hashimoto M, Hossain S, et al. Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol. 2001; 28(4): 266–270.
  38. Calderon F, Kim HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem. 2004; 90(4): 979–988.
  39. Holmquist L, Stuchbury G, Berbaum K, et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther. 2007; 113(1): 154–164.
  40. Hooijmans CR, Pasker-de Jong PCM, de Vries RBM, et al. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2012; 28(1): 191–209.
  41. Cao D, Kevala K, Kim J, et al. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem. 2009; 111(2): 510–521.
  42. Kawakita E, Hashimoto M, Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience. 2006; 139(3): 991–997.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl